Its administration yields an anti-proliferative effect on HER2-positive cells [4] and has been shown to significantly increase response rates in patients with HER2-positive breast cancer, reducing mortality, recurrence, and metastasis rates, and improving overall survival [5–7]. The gene discussed is ERBB2; the disease is breast carcinoma.